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Wnt/-catenin signaling is a critical regulator of skeletal physiology. However, previous studies have mainly
focused on its roles in osteoblasts, while its specific function in osteoclasts is unknown. This is a clinically
important question because neutralizing antibodies against Wnt antagonists are promising new drugs for bone
diseases. Here, we show that in osteoclastogenesis, -catenin is induced during the macrophage colony-
stimulating factor (M-CSF)-mediated quiescence-to-proliferation switch but suppressed during the RANKL-
mediated proliferation-to-differentiation switch. Genetically, -catenin deletion blocks osteoclast precursor
proliferation, while -catenin constitutive activation sustains proliferation but prevents osteoclast differenti-
ation, both causing osteopetrosis. In contrast, -catenin heterozygosity enhances osteoclast differentiation,
causing osteoporosis. Biochemically, Wnt activation attenuates whereas Wnt inhibition stimulates osteoclas-
togenesis. Mechanistically, -catenin activation increases GATA2/Evi1 expression but abolishes RANKL-
induced c-Jun phosphorylation. Therefore, -catenin exerts a pivotal biphasic and dosage-dependent regula-
tion of osteoclastogenesis. Importantly, these findings suggest that Wnt activation is a more effective treatment
for skeletal fragility than previously recognized that confers dual anabolic and anti-catabolic benefits.
Skeletal homeostasis is mainly regulated by bone-resorbing
osteoclasts and bone-forming osteoblasts. Osteoclasts derive
from hematopoietic progenitors (1), while osteoblasts derive
from mesenchymal progenitors (26). During osteoclastogen-
esis, osteoclast progenitors undergo a quiescence-to-prolifera-
tion switch in response to macrophage colony-stimulating fac-
tor (M-CSF), and then osteoclast precursors undergo a
proliferation-to-differentiation switch in response to receptor
activator of NF-B ligand (RANKL) (18, 40). Defects in osteo-
clast function may cause osteopetrosis (34). In contrast, path-
ological stimulation of osteoclast activities occurs in osteopo-
rosis (14a, 14b, 17a), arthritis (13, 17), and bone metastasis of
cancers (20a, 28a). Thus, osteoclasts are critical for bone re-
modeling, but their activity must be controlled (22, 34).
-Catenin is an essential component transducing canonical
Wnt signaling. Wnt activation results in inhibition of glycogen
synthase kinase 3 (GSK-3)-mediated -catenin phosphory-
lation and thereby stabilization of -catenin protein (20). The
Wnt/-catenin pathway is an important regulator of skeletal
physiology. -Catenin deletion in mesenchymal progenitors
blocks osteoblast differentiation by shifting to chondrocyte for-
mation (8, 13a). -Catenin deletion in differentiated osteo-
blasts leads to osteopenia by reducing the expression of osteo-
protegerin (OPG), a decoy RANKL receptor, thus indirectly
elevating osteoclast formation (11, 14). Furthermore, Wnt/-
catenin activation enhances osteoblastogenesis and suppresses
adipogenesis by inhibiting peroxisome proliferator-activated
receptor  (PPAR) (2a, 14d). Therefore, -catenin is re-
quired for osteoblast differentiation and modulates osteoblast
function.
Despite the intense investigation of Wnt/-catenin signaling
in bone biology, previous studies have mainly focused on its
roles in osteoblasts, while its specific functions, if any, in osteo-
clasts are unknown. This is a clinically important question
because Wnt-activating drugs are currently in trials as new
treatment for bone diseases (9, 10, 19, 23, 27, 33). Emerging
evidence revealed that PPAR is an important regulator of
osteoclast lineage commitment and differentiation: on one
hand, PPAR is highly expressed in both osteoclast precursors
and mature osteoclasts (28, 35, 37), and PPAR deletion
causes osteoclast defects manifested as osteopetrosis (37); on
the other hand, activation of PPAR by the diabetic drug
rosiglitazone (BRL, or Avandia) stimulates osteoclast differ-
entiation and bone resorption (18a, 37, 38, 42). Moreover, our
recent study shows that PPAR is also expressed in osteoclast
progenitors: PPAR-tTA TRE-H2BGFP reporter mice (31)
label the entire osteoclast lineage, from osteoclast progenitors
to mature osteoclasts, as a green fluorescent protein-positive
(GFP) hematopoietic bone marrow cell population; as a com-
plement, PPAR-tTA TRE-Cre mice enable genetic manipu-
lation in the osteoclast progenitors and the entire osteoclast
lineage in a spatially and temporally controllable manner
(38a). In light of the mutual inhibition between Wnt and
PPAR in the mesenchymal lineages (30), here, we ask
whether and how Wnt/-catenin signaling also regulates osteo-
clastogenesis.
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MATERIALS AND METHODS
Mice. PPAR-tTA TRE-H2BGFP mice (31), Catnb/lox(ex3) mice (12),
-cateninfl/fl mice (4), Tie2-cre mice (7, 16, 37), LyM-cre mice (6), and Ctsk
(cathepsin K)-cre mice (21) have been described previously. PPAR-tTA TRE-
cre mice were bred with Catnb/lox(ex3) mice to generate PTbCA mice. PPAR-
tTA TRE-cre mice were bred with -cateninfl/fl mice to generate PTbKO and
PTbHet mice. All experiments were performed using littermate cohorts. All
protocols for mouse experiments were approved by the Institutional Animal
Care and Use Committee of the University of Texas Southwestern Medical
Center.
Bone analyses. To evaluate bone volume and architecture by micro-computed
tomography (CT), mouse tibiae were fixed in 70% ethanol. The tibiae were
scanned using a Scanco CT-35 instrument (Scanco Medical) at several resolu-
tions for both overall tibial assessment (14-m resolution) and structural analysis
of trabecular and cortical bone (7-m resolution). Trabecular bone parameters
were calculated using Scanco software to analyze the bone scans from the
trabecular region directly distal to the proximal tibial growth plate. Static histo-
morphometric analyses were conducted using Bioquant Image Analysis software
(Bioquant). Dynamic histomorphometric analyses were performed as previously
described (37), and calcein (20 mg/kg of body weight) was injected into 2-month-
old mice 2 and 10 days before bone collection. TRAP (tartrate-resistant acid
phosphatase) staining of osteoclasts was performed using a leukocyte acid phos-
phatase staining kit (Sigma). ALP staining of osteoblasts was performed using an
alkaline phosphatase staining kit (Sigma). As a bone resorption marker, urinary
or serum C-terminal telopeptide fragments of the type I collagen (CTX-1) was
measured with the RatLaps enzyme immunoassay (EIA) kit (Immunodiagnostic
Systems). Urinary CTX-1 was normalized by urinary creatinine measured with
the Infinity Creatinine Reagent (Thermo Scientific). As a bone formation
marker, serum osteocalcin was measured with the mouse osteocalcin EIA kit
(Biomedical Technologies Inc.).
In vitro osteoclast differentiation. Osteoclasts were differentiated from mouse
bone marrow cells as described previously (15, 37, 38). Briefly, hematopoietic
bone marrow cells were purified with a 40-m cell strainer to remove mesen-
chymal cells and differentiated with 40 ng/ml of M-CSF in  minimal essential
medium (-MEM) containing 10% fetal bovine serum (FBS) for 3 days and then
with 40 ng/ml of M-CSF and 100 ng/ml of RANKL for 3 days (unless otherwise
stated) in the presence or absence of BRL (1 M). Mature osteoclasts were
identified as multinucleated (3 nuclei) TRAP cells. Osteoclast differentiation
was quantified by the RNA expression of RANKL-induced transcription factors
and osteoclast function genes using reverse transcription-quantitative PCR (RT-
QPCR) analysis. Protein expression or phosphorylation was analyzed by Western
blotting. The following reagents were used: recombinant mouse M-CSF,
RANKL, and Wnt3A (R&D Systems) and the GSK3 inhibitor 6-bromoindiru-
bin-3-oxime (BIO) and the inactive control metBIO (Calbiochem). The follow-
ing antibodies were used: anti--catenin and anti-cyclin D1 (BD Biosciences),
anti-c-jun and anti-phospho-c-jun (Cell Signaling), anti-IB (Santa Cruz), and
anti--actin (Sigma).
Osteoclast precursor proliferation assay. Osteoclast precursor proliferation
was quantified using a bromodeoxyuridine (BrdU) cell proliferation assay kit
(GE Healthcare Life Sciences) (2). Mouse bone marrow cells were treated with
M-CSF (40 ng/ml) for 3 days. On day 4, the cells were M-CSF starved for 6 h and
then restimulated with M-CSF for 4 h to induce S phase, during which BrdU was
provided in the culture medium. Cell proliferation was quantified as BrdU
incorporation using the BrdU enzyme-linked immunosorbent assay (ELISA) in
the kit.
Gene expression analyses. RNA was reverse transcribed into cDNA using an
ABI High Capacity cDNA RT Kit and analyzed using real-time quantitative PCR
(SYBR green) in triplicate. All RNA expression was normalized by ribosomal
protein L19.
Flow cytometry. The fluorescence-activated cell sorter (FACS) analyses of
bone marrow cells were performed using a BD FACScan flow cytometer and
phycoerythrin (PE)-conjugated antibody against c-Kit (BD Pharmingen).
Transfection. Bone marrow cells were purified with a 40-m cell strainer to
remove mesenchymal cells and cultured with 40 ng/ml M-CSF overnight. Cells in
suspension were removed, and adherent osteoclast progenitors/precursors were
transfected using FuGene HD (Roche) in the presence of 40 ng/ml M-CSF, with
cDNA-expressing plasmid (or vector control), or with small interfering RNA
(siRNA) (or control) for 3 days before RANKL-induced osteoclast differentia-
tion. Expression plasmids encoding wild-type (WT) c-Jun or the c-JunSer63/73Asp
mutant (JunS63/73D) were generous gifts from D. Bohmann (3, 25). Expression
plasmids encoding WT or constitutively active -catenin were generous gifts
from C. Zhang (41). mGATA2 siRNA, mEvi1 siRNA, and control siRNA were
from Santa Cruz.
Statistical analyses. All statistical analyses were performed with Student’s t
test and represented as means and standard deviations (SD). The P values were
designated as follows: *, P 	 0.05; **, P 	 0.01; ***, P 	 0.005; ****, P 	 0.001;
*****, P 	 0.0005; ****** (or ˆ), P 	 0.0001; NS, nonsignificant (P  0.05).
RESULTS
-Catenin constitutive activation in the osteoclast lineage
causes osteopetrosis. To unravel the functions of canonical
Wnt signaling in osteoclastogenesis, we focused our attention
on -catenin, because it is an obligatory and nonredundant
downstream component of a diverse array of Wnt ligands and
receptors. To establish mouse genetic models harboring
-catenin mutations in the osteoclast lineage, we employed
several Cre drivers, including Tie2-cre for hemagioblast stem
cell targeting (7, 37), PPAR-tTA TRE-cre for osteoclast pro-
genitor targeting (38a), lysozyme (Lyz)-cre for macrophage
precursor targeting (6), and Ctsk-cre for preosteoclast and
mature osteoclast targeting (21). Because of its ability to target
-catenin in osteoclast progenitors without causing embryonic
lethality, we focused our studies on the PPAR driver.
To determine the effects of -catenin activation on osteo-
clastogenesis, we generated a mouse model harboring an in-
ducible -catenin gain-of-function mutation in PPAR cells.
Mice expressing a conditional -catenin mutant allele in which
exon 3, which encodes all the serine and threonine residues
phosphorylated by GSK-3, is flanked by loxP sequences have
been previously generated (Catnb/lox(ex3)) (12). Cre-mediated
deletion of exon 3 prevents -catenin phosphorylation by
GSK-3 and its subsequent degradation, thereby creating a
constitutively active molecule (20). We bred Catnb/lox(ex3)
mice with PPAR-tTA TRE-cre mice to generate PTbCA
(PPAR-tTA TRE-cre-mediated -catenin constitutive activa-
tion) mice (Fig. 1A). The PTbCA mice were compared with
the PPAR-tTA TRE-cre controls (PTctrl). Importantly, this
system conferred a Tet-off temporal control of -catenin acti-
vation. In the absence of doxycycline (Dox), the PTbCA mice
expressed the bCA mutant allele in all the PPAR cells.
When tTA activity was inhibited by Dox from embryonic day 0
(E0), the bCA mutant allele was not activated until Dox was
removed (Fig. 1A).
A series of analyses revealed that the PTbCA mutants ex-
hibited severe osteopetrosis. Strikingly, CT imaging of the
tibiae from 10-month-old mice showed that the trabecular
bone volume/tissue volume (BV/TV) ratio was increased by
27-fold compared to the controls (Fig. 1B and C). Consistently,
the trabecular bones exhibited a greater bone surface (BS)
(4.6-fold), trabecular number (Tb.N.) (3.6-fold), and tra-
becular thickness (Tb.Th.) (8.5-fold), accompanied by a
smaller bone surface/bone volume (BS/BV) ratio (
86%) and
trabecular separation (Tb.Sp.) (
97%) (Fig. 1C). The BV/TV
ratio of the cortical bone and the whole tibia was also signifi-
cantly elevated (Fig. 1C). These results indicate that -catenin
constitutive activation in the osteoclast lineage causes severely
increased bone mass and a highly diminished marrow cavity.
CT analysis of 15-day-old pups showed that this bone pheno-
type had already developed at postnatal day 15 (P15) (http:
//www4.utsouthwestern.edu/wanlab/publications.htm). The
BV/TV ratio was significantly increased in the trabecular
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FIG. 1. -Catenin constitutive activation in the osteoclast lineage causes osteopetrosis. (A) Schematic diagram of PPAR-tTA TRE-cre
Catnb/lox(ex3) (PTbCA) mice. bCA, -catenin constitutively activated. (B and C) CT analysis of the tibiae from PTbCA or control (PTctrl) mice
(10 months old; male; n  3). (B) Representative CT images of the trabecular and cortical bones (scale bars, 10 m) and the entire proximal
tibia (scale bars, 1 mm). (C) Quantification of tibial parameters. The error bars indicate SD. (D) Serum CTX-1 was significantly decreased in
PTbCA mice (15 days old; n 7). (E) Serum osteocalcin was unaltered in PTbCA mice (15 days old; n 16). (F and G) Static histomorphometric
analysis of the femurs showed decreased osteoclast surface (Oc.S/BS) and numbers (Oc.N/B.Ar) (F) but unaltered osteoblast surface (Ob.S/BS)
and numbers (Ob.N/B.Ar) (G) in PTbCA mice (15 days old; male; n  6). B.Ar, bone area. (H) Dynamic histomorphometric analysis with double
calcein labeling (2 months old; male; n  3). (Top) Representative images of the femoral sections illustrating that the distances between the two
calcein labels were similar in PTbCA mice and in the controls. Scale bar, 10 m. (Bottom) Quantification of bone formation rate (BFR/BS) and
mineral apposition rate (MAR). (I) Summary of the bone phenotype in the mouse models that harbor -catenin constitutive activation driven by
different cre drivers targeting different stages of osteoclastogenesis. The results are shown as the percent changes in the mutants compared with
littermate controls (3 months old; male; n 4 to 6; P	 0.05). The parameters include tibial trabecular BV/TV ratio, serum CTX-1 and osteocalcin,
and osteoclast number (Oc.N) per well in a bone marrow osteoclast differentiation assay. *, P 	 0.05; **, P 	 0.01; ***, P 	 0.005; ****, P 	
0.001; ******, P 	 0.0001; n.s., nonsignificant (P  0.05).
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bone, the cortical bone, and the whole tibia (http://www4
.utsouthwestern.edu/wanlab/publications.htm). ELISA ana-
lyses revealed that the bone resorption marker CTX-1 was sig-
nificantly reduced by 51% (Fig. 1D), while the bone formation
marker osteocalcin was unaltered at P15 (Fig. 1E). Consistently,
static histomorphometry showed that the osteoclast surface and
numbers were decreased by 53% and 73%, respectively (Fig. 1F),
while the osteoblast surface and numbers were unaltered (Fig.
1G). In addition, dynamic histomorphometry using double cal-
cein labeling showed that the bone formation rate and mineral
apposition rate were unaltered in the PTbCA mice (Fig. 1H).
Together, these data indicate that -catenin constitutive activa-
tion in the osteoclast lineage causes severe osteopetrosis due to
diminished osteoclast numbers and bone resorption.
To examine the effect of adult-onset -catenin activation,
we treated PTbCA mutants and controls with Dox from E0 to
P30 to turn off bCA and bypass development and then turned
on bCA by removing Dox for 9 months (http://www4
.utsouthwestern.edu/wanlab/publications.htm). These PTbCA
mice also exhibited severely increased bone mass (http://www4
.utsouthwestern.edu/wanlab/publications.htm), indicating that
adult-onset -catenin constitutive activation is sufficient to
cause osteopetrosis. Thus, -catenin in the osteoclast lineage is
also a potent regulator of bone turnover in adulthood that is
independent of its effects on development.
The abnormal osseous environment in osteopetrotic mice often
shifts hematopoiesis from the bone marrow to the spleen (34, 37).
Consistently, the PTbCA mice also developed extramedullary he-
matopoiesis that progressed with age. The number of bone mar-
row cells became significantly less than in the controls at 4
months and diminished to zero at 10 months, which was compen-
sated for by a gradual increase in splenocytes (http://www4
.utsouthwestern.edu/wanlab/publications.htm).
To test whether the osteoclast defects resulted from altered
RANKL or OPG levels, we measured their mRNA expression
in whole tibiae. The RANKL/OPG ratio was not significantly
altered in the PTbCA mutants, nor was the expression of the
receptor of RANKL (RANK) or M-CSF (M-CSFR) (http:
//www4.utsouthwestern.edu/wanlab/publications.htm). These
results indicate that the decreased osteoclast numbers and
resorption are caused by an intrinsic defect in osteoclast dif-
ferentiation.
As complementary approaches to investigate the osteoclast-
autonomous effects of -catenin constitutive activation, we
bred Catnb/lox(ex3) mice with Tie2-cre, Lyz-cre, or Ctsk-cre
mice to generate Tie2-bCA, Lyz-bCA, and Ctsk-bCA mice,
respectively. As summarized in Fig. 1I, Tie2-bCA mice were
embryonic lethal, likely due to the targeting of all other hema-
topoietic lineages and endothelial cells besides osteoclasts (7,
37). Importantly, both Lyz-bCA and Ctsk-bCA mice also ex-
hibited an increased BV/TV ratio and decreased bone resorp-
tion, yet unaltered bone formation (Fig. 1I). Together, these
results strongly support the notion that -catenin constitutive
activation in the osteoclast lineage results in osteopetrosis.
-Catenin constitutive activation blocks osteoclast differen-
tiation and sustains precursor proliferation. To investigate the
effects of -catenin constitutive activation on osteoclast differ-
entiation, we employed an in vitro system. We purified hema-
topoietic bone marrow (BM) cells with a 40-m cell strainer to
remove mesenchymal cells, allowing the assessment of osteo-
clast-autonomous defects (http://www4.utsouthwestern.edu
/wanlab/publications.htm). BM cells from P15 PTbCA mutants
or controls were differentiated with M-CSF and RANKL, with
or without BRL (Fig. 2A). In the control cultures, the forma-
tion of multinucleated TRAP mature osteoclasts was trig-
gered by RANKL and further stimulated by BRL. In contrast,
RANKL and BRL failed to induce osteoclast formation in the
PTbCA mutant cultures (Fig. 2B). Consistently, the induction of
key transcription factors (Fig. 2C) and osteoclast function genes
(Fig. 2D) was severely blunted. Similar results were observed in
splenocyte osteoclast differentiation cultures (http://www4
.utsouthwestern.edu/wanlab/publications.htm). Furthermore, os-
teoclast differentiation was also significantly diminished for the
BM cells from Lyz-bCA mice and Ctsk-bCA mice compared with
their controls (Fig. 1I). These results indicate that -catenin con-
stitutive activation leads to a cell-autonomous blockade in oste-
oclastogenesis.
We hypothesized that -catenin constitutive activation pre-
vented the RANKL-induced proliferation-to-differentiation
switch; thus, we tested whether it increased osteoclast precur-
sor proliferation in vivo and in vitro. First, we examined osteo-
clast precursors in vivo using the PPAR-tTA TRE-H2BGFP
reporter mice, which labeled osteoclast progenitors and pre-
cursors as GFP bone marrow cells. We bred PTbCA mice
with TRE-H2BGFP (THG) mice (14c, 36a) to generate
PTbCA-THG mutants or PTctrl-THG controls (Fig. 2E). Bone
marrow cells were isolated from these mice or GFP
 control
mice and stained with an antibody against the progenitor cell
marker c-Kit or an isotype control. FACS analysis revealed
that the total GFP population was increased by 2.4-fold in
PTbCA-THG mutants compared to PTctrl-THG controls (Fig.
2F). Moreover, both osteoclast progenitors (GFP/cKit) and
osteoclast precursors (GFP/cKit
) were increased, by 2.9-
and 2.3-fold, respectively (Fig. 2F).
Second, we compared osteoclast precursor proliferation in
vitro. Bone marrow cells were cultured with M-CSF for 3 days
and then M-CSF starved for 6 h to synchronize the cell cycle
before being restimulated with M-CSF for 4 h to induce S
phase. Proliferation was quantified as BrdU incorporation dur-
ing the M-CSF restimulation (2) (Fig. 2G, left). The results
showed that osteoclast precursor proliferation was increased
by 2.5-fold in the PTbCA cultures compared to the control
cultures (Fig. 2G, right). These data indicate that -catenin
constitutive activation in the osteoclast lineage blocks osteo-
clast differentiation by sustaining osteoclast precursor prolifer-
ation, thus impairing the proliferation-to-differentiation
switch.
-Catenin heterozygosity in the osteoclast lineage causes
osteoporosis by accelerating osteoclast differentiation. To fur-
ther investigate the physiological functions of -catenin in the
osteoclast lineage, we next relied on a loss-of-function ap-
proach. Mice in which loxP sites had been introduced 5 of
exon 2 and 3 of exon 6 of -catenin (-cateninfl/fl) have been
generated previously to achieve conditional -catenin deletion
(4). We bred -cateninfl/fl mice with PPAR-tTA TRE-cre
mice to generate PPAR-tTA TRE-cre -cateninfl/ heterozy-
gous mice (PTbHet) and PPAR-tTA TRE-cre -cateninfl/fl
knockout (KO) mice (PTbKO) (Fig. 3A).
Analysis of the PTbHet mice revealed that -catenin
heterozygosity in the osteoclast lineage caused osteoporosis, an
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FIG. 2. -Catenin constitutive activation blocks osteoclast differentiation and sustains osteoclast precursor proliferation. (A) Schematic
diagram illustrating the osteoclast differentiation assay. (B) Representative images of TRAP-stained osteoclast differentiation cultures. Bone
marrow cells were isolated from PTbCA mutants or littermate controls (15 days old; n  6). Mature osteoclasts were identified as multinucleated
TRAP (purple) cells; the osteoclast number/well was determined and is shown as the average  SD. Scale bar, 25 m. Veh, vehicle. (C and D)
RANKL-induced and BRL-stimulated induction of transcription factors (C) and osteoclast functional genes (D) was impaired in PTbCA cultures
(n  6). R, RANKL; V, vehicle; B, BRL. The error bars indicate SD. (E) Diagram of PPAR-tTA TRE-Cre Catnb/lox(ex3) TRE-H2BGFP
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opposite phenotype from osteopetrosis. CT imaging showed
that 6-month-old PTbHet mice exhibited significantly reduced
trabecular bone compared to PTctrl mice (Fig. 3B), with a
smaller BV/TV ratio (
67%); less BS (
59%), Tb.N (
48%),
and Tb.Th (
40%); and a greater BS/BV ratio (50%) and
more Tb.Sp (94%) (Fig. 3C). Consistently, the BV/TV ratios
of the cortical bone and the whole tibia were also decreased
(Fig. 3C). The bone loss in PTbHet mice resulted from in-
creased bone resorption marker (Fig. 3D) and osteoclast sur-
face/numbers (Fig. 3E) but unaltered bone formation marker
(Fig. 3F), osteoblast surface/numbers (Fig. 3G), and bone for-
mation/mineral apposition rates (Fig. 3H).
An in vitro bone marrow differentiation assay illustrated that
PTbHet cultures developed more and larger mature osteo-
clasts than PTctrl cultures (Fig. 3I), which was confirmed by
the higher induction rate of osteoclast markers by RANKL and
BRL (Fig. 3J). Moreover, in vitro osteoclast precursor prolif-
eration was markedly decreased in the PTbHet cultures (Fig.
3K). To determine the effect of -catenin heterozygosity on
osteoclast precursors in vivo, we bred PTbHet mice with THG
reporter mice. FACS analysis showed that the percentage of
osteoclast precursors (GFP cells) in the bone marrow was
significantly reduced in the PTbHet-THG mice compared with
the PTctrl-THG mice (Fig. 3L). These results indicate that
-catenin dosage reduction in the osteoclast lineage by
heterozygosity accelerates the proliferation-to-differentiation
switch and enhances osteoclastogenesis.
-Catenin deletion in the osteoclast lineage causes osteope-
trosis by preventing osteoclast precursor proliferation. Provoc-
atively, the PTbKO mice exhibited osteopetrosis. CT imaging
showed that 6-month-old PTbKO mice displayed significantly
more trabecular bone than PTctrl mice (Fig. 3B), with a greater
BV/TV ratio (106%) and more BS (65%), Tb.N (53%), and
Tb.Th (33%), accompanied by a smaller BS/BV ratio (
33%)
and less Tb.Sp (
62%) (Fig. 3C). The BV/TV ratio of the cortical
bone and the whole tibia was also increased (http://www4
.utsouthwestern.edu/wanlab/publications.htm). CTX-1 and osteo-
clast surface/numbers were significantly reduced (Fig. 3D and E),
while osteocalcin, osteoblast surface/numbers, and bone forma-
tion/mineral apposition rates were unaltered (Fig. 3F to H). This
is in line with the fact that -catenin was efficiently deleted in
osteoclasts, but not in osteoblasts (http://www4.utsouthwestern
.edu/wanlab/publications.htm). As is often seen in osteopetrotic
mice, PTbKO mice also displayed extramedullary hematopoiesis
(http://www4.utsouthwestern.edu/wanlab/publications.htm).
An in vitro differentiation assay showed that -catenin dele-
tion impaired osteoclastogenesis (Fig. 3I) and osteoclast
marker induction (Fig. 3J). Moreover, in vitro osteoclast pre-
cursor proliferation was markedly decreased in the PTbKO
cultures compared to PTctrl or PTbHet cultures (Fig. 3K). To
determine the effect of -catenin deletion on osteoclast pre-
cursors in vivo, we bred PTbKO mice with THG reporter mice.
FACS analysis showed that the percentage of osteoclast pre-
cursors (GFP cells) in the bone marrow was significantly
reduced in the PTbKO-THG mice compared with PTctrl-THG
or PTbHet-THG mice (Fig. 3L). The simultaneous blockade of
both precursor proliferation and osteoclast differentiation sug-
gested that -catenin deletion impairs the quiescence-to-pro-
liferation switch of the osteoclast progenitors.
As complementary approaches to investigate osteoclast-
autonomous regulation by -catenin loss-of-function in vivo, we
also assessed the effects of Tie2-cre-mediated -catenin dele-
tion in hemangioblast stem cells, Lyz-Cre-mediated -catenin
deletion in macrophage precursors, and Ctsk-cre-mediated
-catenin deletion in preosteoclasts and mature osteoclasts.
Tie2-bKO mice were born at below a Mendelian ratio (8%
rather than 25%), indicating partial embryonic lethality. None-
theless, Tie2-bKO mice also exhibited osteopetrosis while
Tie2-bHet mice also exhibited osteoporosis due to osteoclast
defects, similar to PTbKO and PTbHet mice, respectively (Fig.
3M). Furthermore, both Lyz-bKO and Ctsk-bKO mice dis-
played osteoporosis due to increased bone resorption, and
Lyz-bHet and Ctsk-bHet mice exhibited an intermediate bone
loss phenotype (Fig. 3M). Together, these gain- and loss-of-
function genetic models based on different cre drivers all
strongly support the cell-autonomous and dosage-dependent
regulation of osteoclastogenesis by -catenin: a minimum
threshold of -catenin is required for the quiescence-to-pro-
liferation switch of the osteoclast progenitors, yet above this
threshold, attenuated -catenin activity accelerates whereas
elevated -catenin activity impedes the proliferation-to-differ-
entiation switch of the osteoclast precursors. Consequently,
-catenin constitutive activation inhibits osteoclastogenesis
and -catenin suppression in the macrophage precursors ac-
celerates osteoclastogenesis, yet complete -catenin deletion
in the osteoclast progenitors blocks osteoclastogenesis.
Ectopic -catenin expression or Wnt activation attenuates
osteoclast differentiation. To further determine whether Wnt
activation suppresses osteoclast differentiation in a cell-auton-
omous manner, we undertook three approaches using the in
vitro BM differentiation assay. First, we asked whether ectopic
-catenin expression could confer an osteoclast differentiation
blockade. WT BM cells were transfected with a vector control
or an expression plasmid encoding either WT or constitutively
active -catenin before differentiation. In the vector-trans-
fected control cultures, many mature osteoclasts developed
after 11 days of differentiation. In contrast, the WT -catenin-
transfected cultures developed fewer and smaller osteoclasts,
and the constitutively active -catenin-transfected cultures
rarely developed osteoclasts but largely remained mononu-
clear precursors (Fig. 4A and B). This was confirmed by the
impaired osteoclast marker induction, due to -catenin over-
expression (Fig. 4C). These results showed that ectopic
-catenin expression inhibits osteoclastogenesis.
(PTbCA THG) mice. (F) The osteoclast precursor population was increased in PTbCA THG mice in vivo compared to littermate controls (PTctrl
THG). Bone marrow cells were stained with a PE-cKit antibody or a PE-isotype control and analyzed by FACS. (Top) Representative histograms.
(Bottom) Percentages of GFP and c-Kit cells in the bone marrow cell population (n  6). (G) Bone marrow-derived osteoclast precursors from
PTbCA mice showed increased proliferation in response to M-CSF in vitro. (Left) Schematic diagram of the proliferation assay. (Right)
Quantification of cell proliferation by BrdU incorporation (n  6). *, P 	 0.05; **, P 	 0.01; ****, P 	 0.001; n.s., nonsignificant (P  0.05).
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FIG. 3. -Catenin heterozygosity enhances osteoclast differentiation, but -catenin deletion suppresses osteoclast precursor proliferation.
(A) Schematic diagram of the PPAR-tTA TRE-cre -cateninfloxed/floxed (PTbKO) mice. (B and C) CT analysis of the tibiae from PTbHet,
PTbKO, or PTctrl mice (6 months old; male; n  5). (B) Representative images of the trabecular bone of the tibial metaphysis (top; scale bars,
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Second, we asked whether Wnt activation by GSK3 inhi-
bition could suppress osteoclast differentiation. The GSK3
inhibitor LiCl, but not the inactive control NaCl, attenuated
osteoclast differentiation (Fig. 4D and E) and osteoclast
marker induction (Fig. 4F). Similar results were observed using
another GSK3 inhibitor, BIO (29). BIO dose-dependently
suppressed osteoclast differentiation (Fig. 4G and H) and os-
teoclast marker induction (Fig. 4I), whereas the inactive con-
trol metBIO (29) had no effect (Fig. 4G, H, and J). These
results showed that GSK3 inhibition suppresses osteoclasto-
genesis.
Third, we asked whether exogenous Wnt agonist could in-
hibit osteoclast differentiation. The results showed that Wnt3A
treatment also dose-dependently attenuated osteoclast differ-
entiation (Fig. 4K and L). Interestingly, Western blot analyses
(Fig. 4M) revealed that -catenin protein was highly expressed
in the proliferating precursors (lane 1) but downregulated
upon RANKL treatment (lane 2) and further suppressed by
BRL (lane 5), and Wnt3A treatment dose-dependently
blocked this -catenin protein downregulation in response to
RANKL and BRL. Together, these results further illustrated
that activation of Wnt/-catenin signaling attenuates osteoclas-
togenesis in a cell-autonomous manner.
Biochemical Wnt inhibition enhances osteoclast differenti-
ation. Complementary to the genetic strategy, we employed a
biochemical approach to further investigate the effects of Wnt
inhibition on osteoclastogenesis. Bone marrow differentiation
cultures were cotreated with the IWR compound (inhibitors of
Wnt response, i.e., IWRendo), which abrogates Axin degrada-
tion, or the inactive control IWRexo at increasing doses (5). In
the absence of IWR, mature osteoclasts, which normally take
10 days to appear, rarely formed after 6 days; in contrast, in the
presence of IWR, mature osteoclasts developed precociously,
with a dose-dependent increase in number and size, whereas
the IWRexo inactive control had no effect (Fig. 5A and B).
Consistently, the expression of osteoclast markers was also
dose-dependently elevated by IWR, normalized by the IWR-
exo control (Fig. 5C). The accelerated osteoclast differentia-
tion correlated with dose-dependently decreased precursor
proliferation by IWR, but not the IWRexo control (Fig. 5D).
As a result, osteoclastogenesis was enhanced by IWR, with the
peak induction at 2 to 4 M (Fig. 5). Interestingly, a higher
dose of IWR (10 M) attenuated this stimulating effect (Fig.
5A to C). This was not due to any toxicity, because the IWRexo
control did not decrease cell proliferation at 10 M (Fig. 5D).
These data are consistent with the in vivo observation that
-catenin heterozygosity promoted bone resorption, whereas
-catenin deletion suppressed bone resorption (Fig. 3). In
summary, these results provide further evidence that Wnt/-
catenin signaling regulates osteoclastogenesis in a cell-auton-
omous and dosage-dependent manner.
Biphasic regulation of -catenin and cyclin D1 during os-
teoclastogenesis. To determine the molecular mechanisms by
which -catenin regulates osteoclastogenesis, we first exam-
ined -catenin protein levels during a time course of osteoclast
differentiation. -Catenin protein was induced upon M-CSF
stimulation and highly expressed in the proliferating osteoclast
precursors (day 3); however, it was downregulated upon
RANKL treatment and further suppressed by BRL (Fig. 6A).
The cyclin D1 gene is a well-known -catenin target gene that
mediates its proliferation-enhancing effect (32). Cyclin D1
mRNA exhibited a biphasic pattern similar to that of -catenin
protein during osteoclastogenesis (Fig. 6B), and so did cyclin
D1 protein (Fig. 6A). Interestingly, BRL attenuated both
-catenin and cyclin D1 expression, which was consistent with
its pro-osteoclastogenic effect (Fig. 6A and B). These results
indicate that -catenin and cyclin D1 are induced in response
to M-CSF to promote the quiescence-to-proliferation switch in
the osteoclast progenitors but are downregulated in response
to RANKL to permit the proliferation-to-differentiation switch
in the osteoclast precursors.
-Catenin stimulates GATA2/Evi1 expression but blocks
c-Jun activation. The transcription factor GATA2 is required
to generate osteoclast progenitors (36, 39). We found that
GATA2 mRNA was highly expressed in osteoclast progenitors
and precursors on day 1 but downregulated during differenti-
ation (Fig. 6C). Western blot analysis showed that -catenin
protein was downregulated by RANKL and further suppressed
by BRL in the PTctrl cultures on day 6 but remained consti-
tutively high in the PTbCA cultures (Fig. 6D). As a result,
GATA2 mRNA expression was significantly elevated in the
PTbCA cultures compared with controls (Fig. 6E). The onco-
genic transcription factor Evi1 (ecotropic viral integration site
1) is required for GATA2 activation and hematopoietic pro-
10 m) and the entire proximal tibia (bottom; scale bars, 1 mm). (C) Quantification of trabecular bone volume and architecture. The asterisks
indicate the P value comparing PTctrl and mutant (PTbHet or PTbKO) mice; the pluses indicate the P value comparing PTbKO and PTbHet mice.
The error bars indicate SD. (D) Urinary CTX-1 (normalized to creatinine) was increased in PTbHet mice but decreased in PTbKO mice compared
with littermate controls (n  5). (E) Static histomorphometry showed that osteoclast surface and numbers were increased in the PTbHet mice but
decreased in the PTbKO mice (n  5). (F) Serum osteocalcin was unaltered in PTbHet or PTbKO mice (n  5). (G) Static histomorphometry
showed that osteoblast surface and numbers were unaltered (n  5). (H) Dynamic histomorphometry showed unaltered bone formation rate
(BFR) and mineral apposition rate (MAR) (n  3). (I) In vitro bone marrow osteoclast differentiation was enhanced for PTbHet mice but
suppressed for PTbKO mice (n  3). Mature osteoclasts were identified as multinucleated TRAP (purple) cells; the osteoclast number/well was
determined and is shown as the average SD. Scale bar, 25 m. (J) RANKL-induced and BRL-stimulated induction of transcription factor (c-fos)
and osteoclast functional gene (TRAP) (n  3). R, RANKL; V, vehicle; B, BRL. (K) Bone marrow-derived osteoclast precursors from PTbHet
and PTbKO mice showed decreased proliferation in response to M-CSF in vitro (n  3). (L) Percentage of osteoclast precursors (GFP) in the
bone marrow (BM) was decreased in PTbHet and PTbKO TRE-H2BGFP (THG) reporter mice compared with controls in vivo (n  3). (M)
Summary of the bone phenotype in the mouse models that harbor -catenin heterozygosity or deletion driven by different cre drivers targeting
different stages of osteoclastogenesis. The results are shown as the percent changes in the Het or KO mutants compared with littermate controls
(3 months old; male; n 4 to 6; P	 0.05). Parameters include tibial trabecular BV/TV ratio, serum CTX-1 and osteocalcin, and osteoclast number
(Oc.N) per well in a bone marrow osteoclast differentiation assay. *, P 	 0.05; ** or , P 	 0.01; *** or , P 	 0.005; **** or ,
P 	 0.001; *****, P 	 0.0005; ******, P 	 0.0001; n.s., nonsignificant (P  0.05).
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genitor proliferation (40a). Evi1 expression was also increased
by 50- to100-fold in the PTbCA cultures compared with the
controls (Fig. 6F). In contrast, the expression of PU.1, another
transcription factor critical for myeloid development, was not
affected (Fig. 6G). Consistently, the GSK3 inhibitor LiCl, but
not the inactive control NaCl, also significantly increased
GATA2 and Evi1 expression (Fig. 6H). Furthermore, siRNA-
mediated knockdown of GATA2 or Evi1 partially rescued the
FIG. 4. Ectopic -catenin expression or biochemical Wnt activation attenuates osteoclast differentiation. (A to C) Ectopic overexpression of wild-type
-catenin (bWT) or a constitutively active -catenin mutant (bCA) attenuated osteoclast differentiation. Bone marrow cells were nontransfected (NT)
or transfected with a -catenin plasmid or a vector (Vec) control before RANKL treatment. (A) Representative images of TRAP-stained osteoclast
differentiation cultures. Scale bars, 25 m. (B) Quantification of the number of multinucleated (3 nuclei) TRAP mature osteoclasts (n 6). The error
bars indicate SD. (C) Expression of a representative osteoclast marker (Ctsk) and -catenin (n  3). (D to G) GSK3 inhibition by LiCl attenuated
osteoclast differentiation. Bone marrow cells were treated with LiCl or an inactive control, NaCl, at the indicated concentrations. (D) Representative
images of TRAP-stained osteoclast differentiation cultures. Scale bars, 25 m. (E) Quantification of multinucleated (3 nuclei) TRAP mature
osteoclasts (n 6). (F) Expression of a representative osteoclast function gene (TRAP) (n 3). (G to J) GSK3 inhibition by BIO attenuated osteoclast
differentiation. Bone marrow cells were treated with BIO or an inactive control, metBIO, at the indicated concentrations. (G) Representative images of
TRAP-stained osteoclast differentiation cultures. Scale bars, 25 m. (H) Quantification of multinucleated (3 nuclei) TRAP mature osteoclasts (n 
6). (I and J) Expression of a representative osteoclast function gene was suppressed by BIO in a dose-dependent manner (I), but not by the inactive
control metBIO (J) (n  3). (K to M) The Wnt agonist Wnt3A attenuated osteoclast differentiation. Bone marrow cells were treated with Wnt3A or
vehicle control at the indicated concentrations. (K) Representative images of TRAP-stained osteoclast differentiation cultures. Scale bars, 25 m.
(L) Quantification of multinucleated (3 nuclei) TRAP mature osteoclasts (n 6). (M) -Catenin downregulation by RANKL and BRL was abolished
by Wnt3A in a dose-dependent manner. Whole-cell extract was collected after 6 days of differentiation and analyzed by Western blotting. The results were
quantified as the -catenin/-actin ratio. ˆ, P 	 0.0001; n.s, nonsignificant (P  0.05).
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osteoclast differentiation blockade in the PTbCA cultures (Fig.
6I). These results indicate that -catenin activation increases
GATA2 and Evi1 expression, thereby sustaining osteoclast
precursor proliferation, and RANKL-induced and BRL-stim-
ulated -catenin downregulation is required for GATA2 and
Evi1 suppression.
We next examined the effects of -catenin activation on
RANKL signaling. RANKL-induced and BRL-stimulated c-
Jun phosphorylation was abolished in the PTbCA cultures,
while IB degradation was unaffected, suggesting that
-catenin activation blocks osteoclast differentiation by inhib-
iting c-Jun activity (Fig. 7A). Consistently, the GSK3 inhibi-
tor LiCl, but not the inactive control NaCl, also specifically
suppressed RANKL- and BRL-induced c-Jun phosphorylation
without affecting IB degradation (Fig. 7B). We next tested
whether ectopic c-Jun activation could rescue the osteoclast
differentiation blockade in the PTbCA cultures. Bone marrow
cells from PTbCA mice were transfected with a vector control
or an expression plasmid encoding either WT c-Jun (JunWT)
or c-JunSer63/73Asp (JunS63/73D), a constitutively active mutant
in which serines 63 and 73 were mutated to aspartic acid (a
phosphormimetic mutation) (3, 25). The results showed that
FIG. 5. Biochemical Wnt inhibition enhances osteoclast differentiation. (A to C) Bone marrow osteoclast differentiation cultures were treated
with the Wnt inhibitor IWRendo or an inactive control, IWRexo, at the indicated concentrations in the presence or absence of RANKL, with or
without BRL. Osteoclast formation was analyzed 6 days after differentiation (3 days after RANKL addition). (A) Representative images of
TRAP-stained osteoclast differentiation cultures. Scale bars, 25 m. (B) Quantification of multinucleated (3 nuclei) TRAP mature osteoclasts
(n  6). The error bars indicate SD. (C) Relative mRNA expression of osteoclast marker genes in the differentiation cultures treated with
IWRendo, normalized by that treated with the IWRexo inactive control (n  6). (D) Proliferation of bone marrow-derived osteoclast precursors
in response to M-CSF was inhibited by IWRendo, but not by the IWRexo inactive control, in a dose-dependent manner (n 6). *, P	 0.05; ****,
P 	 0.001; *****, P 	 0.0005; ******, P 	 0.0001; n.s., nonsignificant (P  0.05).
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ectopic expression of c-Jun partially rescued the osteoclast
differentiation blockade, with the JunS63/73D mutant more
effective than JunWT (Fig. 6C to E). The transfection effi-
ciency was 50% (http://www4.utsouthwestern.edu/wanlab
/publications.htm), and c-Jun was significantly overexpressed
(Fig. 7F). These results indicate that -catenin activation pre-
vents c-Jun phosphorylation, thereby blocking osteoclast dif-
ferentiation, and that RANKL-induced and BRL-stimulated
-catenin downregulation is required for c-Jun activation. To-
gether, these data provide critical molecular insights into how
-catenin employs distinct mechanisms to exert biphasic reg-
ulation of osteoclastogenesis: it promotes M-CSF-mediated
precursor proliferation by inducing GATA2 and Evi1 expres-
sion, and it blocks RANKL-mediated osteoclast differentiation
by impairing c-Jun activation.
DISCUSSION
In this study, we have identified the canonical Wnt/-catenin
pathway as a previously unrecognized yet critical regulator of
osteoclastogenesis. -Catenin protein is induced during the
quiescence-to-proliferation switch of the osteoclast progeni-
tors in response to M-CSF but downregulated during the pro-
liferation-to-differentiation switch in response to RANKL
(Fig. 7G). Genetically, -catenin deletion impairs osteoclast
precursor proliferation, while -catenin constitutive activation
FIG. 6. -Catenin stimulates GATA2 and Evi1 expression. (A to C) Time course expression analyses of in vitro bone marrow osteoclast
differentiation (n 3). -Catenin and cyclin D1 protein (A), as well as cyclin D1 mRNA (B), were upregulated during M-CSF-mediated precursor
proliferation but downregulated during RANKL-mediated osteoclast differentiation and further suppressed by BRL. The error bars indicate SD.
d, day. (C) GATA2 mRNA expression was downregulated during osteoclastogenesis and suppressed by BRL. The arrows in panels B and C
indicate that M-CSF was added on day 0 and that RANKL and M-CSF were added on day 3. (D) The -catenin protein level was downregulated
by RANKL and further reduced by BRL in control osteoclast differentiation cultures but remained constitutively high in PTbCA cultures.
Whole-cell extract was collected on day 6 and analyzed by Western blotting. (E to G) Gene expression in PTbCA and control cultures on day 6
of differentiation from bone marrow (BM) or splenocytes (SP) (n  3). GATA2 (E) and Evi1 (F) mRNA expression was increased in PTbCA
cultures. (G) PU.1 mRNA expression was unaltered in PTbCA cultures. (H) The GSK3 inhibitor LiCl (3 mM), but not the inactive control NaCl
(3 mM), increased GATA2 and Evi2 mRNA expression after 6 days of differentiation (n  3). The P values compare treatment with the control.
(I) GATA2 or Evi1 knockdown partially rescued the osteoclast differentiation blockade in PTbCA cultures. Bone marrow cells were transfected
with GATA2 siRNA, Evi1 siRNA, or a control siRNA for 3 days before RANKL stimulation. Representative osteoclast marker genes were
measured by RT-QPCR (n  3). The P values compare RANKL with Veh. *, P 	 0.05; **, P 	 0.01; ***, P 	 0.005; ****, P 	 0.001; *****,
P 	 0.0005; ******, P 	 0.0001; n.s., nonsignificant (P  0.05).
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sustains precursor proliferation, both blocking osteoclast dif-
ferentiation and causing osteopetrosis. In contrast, -catenin
dosage reduction by heterozygosity enhances osteoclast differ-
entiation and causes osteoporosis. Biochemically, -catenin
activation by GSK3 inhibitors or a Wnt ligand attenuates
osteoclastogenesis, whereas -catenin suppression by a Wnt
inhibitor or a PPAR agonist stimulates osteoclastogenesis.
Mechanistically, -catenin activation promotes precursor pro-
liferation by elevating GATA2 and Evi1 expression and blocks
osteoclast differentiation by preventing c-Jun phosphorylation.
FIG. 7. -Catenin blocks c-Jun activation. (A) RANKL-induced and BRL-stimulated c-Jun phosphorylation, but not IB degradation, were
abolished in PTbCA cultures. Bone marrow cells from PTbCA or PTctrl mice were treated with M-CSF for 3 days in the presence or absence of
BRL and then stimulated with RANKL for 15 or 30 min. Whole-cell extract was analyzed by Western blotting. (B) RANKL-induced and
BRL-stimulated -catenin downregulation and c-Jun phosphorylation, but not IB degradation, were abolished by the GSK3 inhibitor LiCl, but
not by the inactive control, NaCl. Whole-cell extract was collected on day 6 and analyzed by Western blotting. (C to F) Ectopic overexpression of
either a wild-type c-Jun (JunWT) or a constitutively active c-Jun mutant (JunS63/73D) rescued the osteoclast differentiation blockade in PTbCA
cultures. Bone marrow cells were transfected with a c-Jun plasmid or a vector control (Vec) and differentiated with RANKL and M-CSF, with or
without BRL. (C) Representative images of TRAP-stained osteoclast differentiation cultures. Scale bars, 25 m. (D) Quantification of multinu-
cleated (3 nuclei) TRAP mature osteoclasts (n 6). The error bars indicate SD. (E) Quantification of the mRNA expression of a representative
osteoclast functional gene (n  3). (F) Quantification of the mRNA expression of c-Jun (n  3). (G) Simplified model illustrating the biphasic
and dosage-dependent regulation of osteoclastogenesis by -catenin. -Catenin and its cyclin D1 target gene are induced by M-CSF to promote
the quiescence-to-proliferation switch but are downregulated by RANKL to permit the proliferation-to-differentiation switch. -Catenin dosage
reduction, for example, by the PPAR agonist BRL, accelerates osteoclastogenesis. *, P 	 0.05; **, P 	 0.01; ***, P 	 0.005; ****, P 	 0.001;
*****, P 	 0.0005; ******, P 	 0.0001; n.s., nonsignificant (P  0.05).
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Therefore, -catenin exerts a biphasic regulation of osteoclas-
togenesis: its induction is required for M-CSF-mediated precur-
sor proliferation, yet its degradation is required for RANKL-
mediated osteoclast differentiation. Moreover, -catenin controls
osteoclast differentiation in a dosage-dependent manner: a min-
imum threshold of -catenin is required for osteoclast progeni-
tors to proliferate, yet above this threshold, -catenin activation
suppresses osteoclast differentiation, while -catenin attenuation
accelerates osteoclast differentiation.
In order to understand the full spectrum of -catenin func-
tions in osteoclastogenesis, it is essential to target the entire
osteoclast lineage from osteoclast progenitors to mature osteo-
clasts. However, the intrinsic multipotent property of stem/
progenitor cells renders it impossible to specifically target the
osteoclast lineage. Therefore, by establishing a suite of genetic
models using different cre drivers targeting different stages of
osteoclastogenesis, we were able to extract the cell-autono-
mous regulation of osteoclastogenesis by -catenin. The
PPAR-driven -catenin models permit osteoclast progenitor
targeting without the embryonic lethality seen in the Tie2-
driven -catenin models. Importantly, the bone phenotype in
the PPAR-driven -catenin models was not due to any MSC
or osteoblast targeting, because (i) the reported MSC-bKO
mice were embryonic lethal (8) while, in contrast, the PTbKO
mice were viable; (ii) the reported osteoblast-bCA mice died a
few days after weaning with a BV/TV ratio of 23% (11) while,
in contrast, the PTbCA mice lived for 12 months with a
BV/TV ratio of 80%; (iii) osteoblast numbers and bone for-
mation were largely unaltered in these mice. This strongly
supports the notion that the bone phenotype in these mice was
mainly the result of osteoclast-autonomous defects. Further-
more, although the Lyz-Cre- and Ctsk-cre-driven -catenin
models cannot target osteoclast progenitors, they permit more
specific targeting to macrophage precursors and osteoclasts,
respectively. The results, with Lyz-bCA and Ctsk-bCA mice
exhibiting osteopetrosis while Lyz-bKO and Ctsk-bKO mice
exhibited osteoporosis, confirmed that -catenin constitutive
activation inhibits osteoclastogenesis and -catenin dosage re-
duction in the macrophage precursors stimulates osteoclasto-
genesis. However, Lyz-bKO and Ctsk-bKO mice did not reveal
the critical requirement of -catenin in the quiescence-to-pro-
liferation switch of the osteoclast progenitors, which was un-
covered in the PTbKO and Tie2-bKO mice. Therefore, these
studies also highlight the inducible PPAR-tTA-TRE-cre
driver as a novel strategy for targeting osteoclast progenitors
and the entire osteoclast lineage that is complementary to the
existing cre drivers.
Wnt activation is a promising therapeutic strategy for treat-
ing bone diseases based on its currently known bone forma-
tion-stimulating anabolic effects. For example, a neutralizing
monoclonal antibody (Scl-Ab) against the Wnt antagonist
sclerostin (sost), which is secreted specifically from osteocytes
(27), has been shown to markedly increase bone formation and
reverse estrogen deficiency-induced bone loss (19, 23). Cur-
rently, Scl-Ab is being developed by Amgen as a new anabolic
treatment for bone disorders, such as postmenopausal osteo-
porosis. Furthermore, a neutralizing monoclonal antibody
(BHQ880) against the Wnt antagonist Dickkopf-1 (DKK-1),
which is expressed predominantly in adult bone and upregu-
lated in multiple myeloma (33), has been shown to increase
bone formation in murine models of human multiple myeloma
and rheumatoid arthritis (9, 10). Currently, BHQ880 is being
developed by Novartis as a new approach to promote bone
formation and thereby inhibit tumor-induced osteolysis. Our
findings provide strong evidence that Wnt activation also in-
hibits osteoclast differentiation and bone resorption, illuminat-
ing a previously unrecognized additional anticatabolic benefit.
Consistent with this notion, in a recent first-in-humans study, a
sclerostin monoclonal antibody (AMG 785) not only increased
bone formation marker but also decreased bone resorption
marker in a dose-dependent manner (24). Therefore, bone-
specific activators of Wnt/-catenin signaling may promise an
exciting new class of drugs that can more effectively prevent
and treat skeletal fragility.
In summary, the discovery of novel roles of -catenin in
osteoclastogenesis in this study opens an exciting new path to
future investigations of the ligands, receptors, signal transduc-
ers, and transcription factors that orchestrate the regulation of
osteoclast physiology and pharmacology by the Wnt pathway.
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